Anti-inflammatory effects of DX-890, a human neutrophil elastase inhibitor

被引:18
作者
Dunlevy, Fiona K.
Martin, S. Lorraine [2 ]
de Courcey, Francine
Elborn, J. Stuart
Ennis, Madeleine [1 ]
机构
[1] Queens Univ Belfast, Ctr Infect & Immun, Sch Med Dent & Biomed Sci, Belfast BT9 7BL, Antrim, North Ireland
[2] Queens Univ Belfast, Ctr Med Biol, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland
关键词
Cystic fibrosis; Epithelial; Protease; Airway; INTERLEUKIN-8; GENE-EXPRESSION; FIBROSIS AIRWAY SECRETIONS; EPITHELIAL-CELL LINE; ACUTE LUNG INJURY; CYSTIC-FIBROSIS; PROTEASE INHIBITORS; LEUKOCYTE ELASTASE; INFLAMMATION; INDIVIDUALS; MIGRATION;
D O I
10.1016/j.jcf.2012.02.003
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Neutrophil elastase (NE)-mediated inflammation contributes to lung damage in cystic fibrosis (CF). We investigated if DX-890, a small-protein NE inhibitor, could reduce neutrophil trans-epithelial migration and reduce activity released from neutrophils and NE-induced cytokine expression in airway epithelial cells. Methods: Activated blood neutrophils (CF and healthy) treated +/- DX-890 were assayed for NE activity. Transmigration of calcein-labeled neutrophils was studied using a 16HBE14o(-) epithelial monolayer. IL-8 release from primary nasal epithelial monolayers (CF and healthy) was measured after treatment +/- DX-890 and NE or CF sputum. Results: DX-890 reduced NE activity from neutrophils (CF and healthy) and reduced neutrophil transmigration. DX-890 pre-treatment reduced IL-8 release from epithelial cells of healthy or CF subjects after stimulation with NE and CF sputum sol. All improvements with DX-890 were statistically significant (p<0.05). Conclusions: DX-890 reduces NE-mediated transmigration and inflammation. NE inhibition could be useful in managing neutrophilic airway inflammation in CF. (c) 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:300 / 304
页数:5
相关论文
共 33 条
  • [1] Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis
    Belaaouaj, A
    McCarthy, R
    Baumann, M
    Gao, ZM
    Ley, TJ
    Abraham, SN
    Shapiro, SD
    [J]. NATURE MEDICINE, 1998, 4 (05) : 615 - 618
  • [2] Neutrophil extracellular traps kill bacteria
    Brinkmann, V
    Reichard, U
    Goosmann, C
    Fauler, B
    Uhlemann, Y
    Weiss, DS
    Weinrauch, Y
    Zychlinsky, A
    [J]. SCIENCE, 2004, 303 (5663) : 1532 - 1535
  • [3] Effect of cystic fibrosis exacerbations on neutrophil function
    Brockbank, S
    Downey, D
    Elborn, JS
    Ennis, M
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2005, 5 (03) : 601 - 608
  • [4] Neutrophil elastase induces IL-8 synthesis by lung epithelial cells via the mitogen-activated protein kinase pathway
    Chen, HC
    Lin, HC
    Liu, CY
    Wang, CH
    Hwang, T
    Huang, TT
    Lin, CH
    Kuo, HP
    [J]. JOURNAL OF BIOMEDICAL SCIENCE, 2004, 11 (01) : 49 - 58
  • [5] Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor
    Delacourt, C
    Hérigault, S
    Delclaux, C
    Poncin, A
    Levame, M
    Harf, A
    Saudubray, F
    Lafuma, C
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2002, 26 (03) : 290 - 297
  • [6] Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane
    Delclaux, C
    Delacourt, C
    dOrtho, MP
    Boyer, V
    Lafuma, C
    Harf, A
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1996, 14 (03) : 288 - 295
  • [7] Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4
    Devaney, JM
    Greene, CM
    Taggart, CC
    Carroll, TP
    O'Neill, SJ
    McElvaney, NG
    [J]. FEBS LETTERS, 2003, 544 (1-3) : 129 - 132
  • [8] DORING G, 1995, J IMMUNOL, V154, P4842
  • [9] Dubray C, 2001, 97 ATS INT C AM THOR
  • [10] Inhibition of airway proteases in cystic fibrosis lung disease
    Griese, M.
    Kappler, M.
    Gaggar, A.
    Hartl, D.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2008, 32 (03) : 783 - 795